Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction – is it truly a benign disease?

被引：0
|
作者：
GF How
LT Tan
LC Lim
机构：
[1] Singapore General Hospital,Department of Hematology
来源：
Leukemia | 1998年 / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1166 / 1167
页数：1
相关论文
共 50 条
  • [31] e6a2 BCR-ABL transcript in chronic myeloid leukemia: is it associated with aggressive disease?
    Colla, S
    Sammarelli, G
    Voltolini, S
    Crugnola, M
    Sebastio, P
    Giuliani, N
    HAEMATOLOGICA, 2004, 89 (05) : 611 - 613
  • [32] Molecular responses to tyrosine kinase inhibitors in rare, variant e1a2, e6a2 and e19a2 BCR-ABL chronic myeloid leukaemia
    Langabeer, S. E.
    Crampe, M.
    McCarron, S. L.
    Haslam, K.
    Connaghan, G.
    Perera, K.
    Cahill, M. R.
    Conneally, E.
    BRITISH JOURNAL OF HAEMATOLOGY, 2010, 149 : 74 - 74
  • [33] An accelerrated-phase CML patient with e19a2 junction of BCR/ABL gene - the first case of transplanted CML with micro bcr
    J Polák
    V Koza
    P Cetkovský
    C Haškovec
    Bone Marrow Transplantation, 2000, 25 : 1109 - 1110
  • [34] An accelerated-phase CML patient with e19a2 junction of BCR/ABL gene -: the first case of transplanted CML with micro bcr
    Polák, J
    Koza, V
    Cetkovsky, P
    Haskovec, C
    BONE MARROW TRANSPLANTATION, 2000, 25 (10) : 1109 - 1110
  • [35] An atypical (b3/a3) junction of the bcr/abl gene lacking abl exon a2 in a patient with chronic myeloid leukemia
    Amabile, M
    Martinelli, G
    Terragna, C
    Montefusco, V
    Tabilio, A
    Tura, S
    HAEMATOLOGICA, 1999, 84 (06) : 573 - 575
  • [36] First and second line imatinib treatment in chronic myelogenous leukemia patients expressing rare e1a2 or e19a2 BCR-ABL transcripts
    Andrikovics, Hajnalka
    Nahajevszky, Sarolta
    Szilvasi, Aniko
    Bors, Andras
    Adam, Emma
    Kozma, Andras
    Kajtar, Bela
    Barta, Aniko
    Poros, Anna
    Tordai, Attila
    HEMATOLOGICAL ONCOLOGY, 2007, 25 (03) : 143 - 147
  • [37] A chronic myeloid leukemia case with an atypical (B3/A3) junction of the BCR/ABL gene lacking ABL exon A2.
    Martinelli, G
    Amabile, M
    Rosti, GA
    Ottaviani, E
    Terragna, C
    Montefusco, V
    Tabilio, A
    Tura, S
    BLOOD, 1999, 94 (10) : 277B - 277B
  • [38] Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: Benign course responsive to imatinib with an RT-PCR advisory
    Snyder, DS
    McMahon, R
    Cohen, SR
    Slovak, ML
    AMERICAN JOURNAL OF HEMATOLOGY, 2004, 75 (02) : 92 - 95
  • [39] Identification of e19a2 BCR–ABL fusions (μ-BCR breakpoints) at the DNA level by ligation-mediated PCR
    N Boeckx
    M W J C Jansen
    C Haskovec
    P Vandenberghe
    V H J van der Velden
    J J M van Dongen
    Leukemia, 2005, 19 : 1292 - 1295
  • [40] Y253H mutation appearing in a μ-BCR-ABL (e19a2) CML
    Popovici, Cornel
    Charbonnier, Aude
    Gisserot, Olivier
    Aguilon, Philippe
    Remy, Virginie
    Olschwang, Sylviane
    Mozziconacci, Marie-Joelle
    LEUKEMIA RESEARCH, 2008, 32 (02) : 361 - 362
12345